Hardman & Co Research: Diurnal Group (DNL): First commercial revenues

Hardman & Co: First commercial revenues

Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term 'Adrenal Franchise'. Following approval from the European Commission, Alkindi is being launched in key EU markets through DNL's own commercial infrastructure, starting with Germany and now launched in the UK. Additional territories will follow during 2018 and 2019. Meanwhile, the company is pushing forward with Alkindi and Chronocort clinical trials in the US. Cash at the end of the period was £17.3m.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/04.10.18-first-commercial-revenues.pdf

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.